OBJECTIVE: To evaluate the efficacy and safety of radix astragali and its compound prescription for treatment of β-thalassemia in children. METHODS: This study was a randomized, controlled, double-blind clinical trial. Fifty-seven children with β-thalassemia were randomly assigned to radix astragali, compound prescription (radix astragali+ codonopsis pilosula + tortoise plastron) and placebo control groups after stratifying the patients according to disease type (intermedia and major). The parameters of hematology and safety were assessed after 12 weeks of treatment. RESULTS: After 12 weeks of treatment, the mean Hb elevation levels in children with β-thalassemia intermedia from the compound prescription and the radix astragali groups were 1.21±1.12 and 1.05±0.80 g/dL respectively compared with -(0.28±0.51) g/dL in the placebo control group (P<0.01). Mean Hb levels in the compound prescription and radix astragali groups were significantly higher than in the placebo control group (P<0.05). Therapy with both radix astragali and its compound prescription increased fetal hemoglobin, red blood cell, mean corpuscular hemoglobin and reticulocyte levels in children with β-thalassemia intermedia. The total effective rates were 64% and 62% in children with β-thalassemia intermedia from the compound prescription and radix astragali groups respectively, which was significantly higher than in the placebo control group (9%; P<0.01). Therapy with radix astragali or its compound prescription in children with β-thalassemia major had similar but less favourable effets than the same therapy in children with β-thalassemia intermedia. White blood cell, neutrophil, platelet and hepatic and renal functions were not adversely affected by the medicines. CONCLUSIONS: Therapy with radix astragali or its compound prescription is effective and safe in children with β-thalassemia.
Key words
β-thalassemia /
Radix astragali /
Efficacy /
Fetal hemoglobin /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］Rund D, Rachmilewitz E. Beta-thalassemia ［J］. N Engl J Med, 2005, 353(11): 1135-1146.
［2］Weatherall DJ. Keynote address: the challenge of thalassemia for the developing countries［J］. Ann NY Acad Sci, 2005, 1054: 11-17.
［3］Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications［J］. Hum Mol Genet, 2009, 18(R2): R216-R223.
［4］Perrine SP. Fetal globin induction-can it cure beta thalassemia?［J］. Hematology, Am Soc Hematol Educ Program, 2005, 38-44.
［5］郭志梅，李海军，钱新华. 龟板、黄芪、丹参和党参诱导K562细胞合成γ珠蛋白的实验研究［J］. 中国实验血液学杂志，2008，16（3）：520-524.
［6］郭志梅，李海军，钱新华. 龟板、黄芪、丹参、党参上调K562细胞Gγ-珠蛋白mRNA的表达［J］. 华西药学杂志，2008，23（3）：260-262.
［7］杨敏，赵丹华，钱新华. 黄芪不同提取物对K562细胞向红系分化的诱导作用研究［J］. 解放军医学杂志，2008，33（3）：293-295.
［8］黄为民，钱新华，赵丹华，阳勇. 黄芪多糖对K562细胞胎儿血红蛋白合成和细胞增殖的影响［J］. 实用儿科临床杂志，2009, 24（3）：687-688.
［9］黄为民，钱新华，赵丹华. 黄芪多糖诱导K562细胞γ-珠蛋白基因表达［J］. 南方医科大学学报, 2009, 29(5): 939-942.
［10］Yang M, Qian XH, Zhao DH, Fu SZ. Effects of Astragalus polysaccharide on the erythroid lineage and microarray analysis in K562 cells ［J］. J Ethnopharmacol, 2010, 127(2): 242250.
［11］张之南，沈悌. 血液病诊断及疗效标准 ［M］. 北京:科学出版社, 2007:29-30.
［12］Xu XM, Zhou YQ, Lou GX, Liao C, Zhou M, Chen PY, et al. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening［J］. J Clin Pathol, 2004, 57(5): 517-522.
［13］黄钰君，区小冰，张力，余一平，伍绍国. 广州地区儿童β地中海贫血的发生率及基因检测结果分析［J］. 临床血液学杂志，2006，19（6）：355-357.
［14］黄钰君，伍绍国，区小冰，张力，余一平.儿童地中海贫血的发生率及发病基因分析［J］. 中国优生与遗传杂志，2007，15（6）：28-31.
［15］Muncie HL Jr, Campbell J. Alpha and beta thalassemia［J］. Am Fam Physician, 2009, 80(4): 339-441.
［16］Vichinsky E. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia ［J］. Pediatrics, 2008, 121(6): 1253-1256.
［17］Walters MC. Gene therapy and bone marrow transplantation for thalassemia: changing of the guard?［J］. Mol Ther, 2010, 18(9): 1577.
［18］Pace BS, Zein S. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction［J］. Dev Dyn, 2006, 235(7): 1727-1737.
［19］吴志奎，张新华，刘咏梅，李敏，陈玉英，吕鑫霞，等. 益髓生血颗粒治疗β-地中海贫血患者自身对照比较研究［J］. 中国中医药信息杂志，2007，14（3）：9-11.
［20］郑柳明，张新华，吴志奎，王文权，周天红，韦昭华，等. 益髓生血颗粒治疗重型β珠蛋白生成障碍性贫血的疗效［J］. 实用儿科临床杂志，2009，24（15）：1167-1168.
PDF(1025 KB)
